Published in Liver Transpl on January 01, 2004
Molecular fluorescence, phosphorescence, and chemiluminescence spectrometry. Anal Chem (2006) 0.78
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. Nat Genet (2005) 3.55
Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med (2006) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev Dyn (2006) 2.83
Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol (2005) 2.54
Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion (2004) 2.51
Translational systems biology of inflammation. PLoS Comput Biol (2008) 2.15
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg (2007) 2.12
A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology (2005) 1.82
Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg (2011) 1.77
Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials. Anesth Analg (2011) 1.77
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg (2010) 1.60
Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg (2005) 1.54
The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg (2008) 1.54
Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. Anesthesiology (2016) 1.51
The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg (2010) 1.48
A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg (2005) 1.46
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. J Thorac Cardiovasc Surg (2012) 1.42
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res (2004) 1.42
Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. Paediatr Anaesth (2015) 1.42
Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg (2006) 1.41
Mechanistic simulations of inflammation: current state and future prospects. Math Biosci (2008) 1.40
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg (2006) 1.39
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med (2007) 1.35
Metabolic syndrome and robustness tradeoffs. Diabetes (2004) 1.31
Concepts of blood transfusion in adults. Lancet (2013) 1.28
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
Sepsis-induced disseminated intravascular coagulation, symmetrical peripheral gangrene, and amputations. Crit Care Med (2013) 1.12
A reducing redox environment promotes C2C12 myogenesis: implications for regeneration in aged muscle. Cell Biol Int (2006) 1.11
Rules of engagement. Nature (2007) 1.08
Donation after cardiac death and the anesthesiologist. Anesth Analg (2010) 1.08
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA (2004) 1.07
Architecture, constraints, and behavior. Proc Natl Acad Sci U S A (2011) 1.07
A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion (2011) 1.07
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg (2007) 1.05
Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg (2014) 1.05
Impact of percutaneous coronary intervention performance reporting on cardiac resuscitation centers: a scientific statement from the American Heart Association. Circulation (2013) 1.04
Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem (2004) 1.04
The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg (2005) 1.03
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res (2007) 1.02
Motifs, control, and stability. PLoS Biol (2005) 1.02
A role for endothelin in neuropathic pain after chronic constriction injury of the sciatic nerve. Anesth Analg (2005) 0.98
Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion (2013) 0.96
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol (2012) 0.95
The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg (2004) 0.95
A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Anesth Analg (2011) 0.94
The role of thrombin and protease-activated receptors in pain mechanisms. Thromb Haemost (2010) 0.93
Sod2 overexpression preserves myoblast mitochondrial mass and function, but not muscle mass with aging. Aging Cell (2009) 0.93
Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology (2002) 0.93
Optimal data systems: the future of clinical predictions and decision support. Curr Opin Crit Care (2014) 0.92
Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg (2010) 0.91
Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg (2008) 0.91
Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg (2011) 0.90
Electron paramagnetic resonance assessment of brain tissue oxygen tension in anesthetized rats. Anesth Analg (2003) 0.90
Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. J Anesth (2007) 0.89
Human embryonic stem cell model of ethanol-mediated early developmental toxicity. Exp Neurol (2011) 0.89
Intravenous mononuclear marrow cells reverse neuropathic pain from experimental mononeuropathy. Anesth Analg (2007) 0.88
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg (2013) 0.87
A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg (2008) 0.87
The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg (2002) 0.87
Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg (2010) 0.86
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg (2006) 0.86
Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. Anesth Analg (2002) 0.85
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology (2003) 0.85
Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol (2005) 0.84
The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg (2002) 0.84
Concise review: immunologic lessons from solid organ transplantation for stem cell-based therapies. Stem Cells Transl Med (2013) 0.83
The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg (2012) 0.83
Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology (2002) 0.83
An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg (2005) 0.82
In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. J Cardiothorac Vasc Anesth (2009) 0.82
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. Mol Biosyst (2010) 0.82
Goal-directed coagulation management in the perioperative period of cardiac surgery. J Cardiothorac Vasc Anesth (2013) 0.81
What is blood and what is not? Caring for the Jehovah's Witness patient undergoing cardiac surgery. Anesth Analg (2007) 0.81
A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg (2011) 0.81
ECMO resuscitation after massive pulmonary embolism during liver transplantation. Anesthesiology (2002) 0.81
A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions. Thromb Haemost (2011) 0.80
ED50 and recovery times after propofol in rats with graded cirrhosis. Anesth Analg (2011) 0.80
Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? Chest (2012) 0.80
Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg (2006) 0.80
Transfusion and hemostasis in cardiac surgery. Transfusion (2008) 0.80
Aprotinin in cardiac surgery. N Engl J Med (2006) 0.80
The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. Br J Haematol (2006) 0.80
Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis (2007) 0.80
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J (2006) 0.80